Design, rationale, and baseline characteristics of a pilot randomized clinical trial of nicotine treatment for pulmonary sarcoidosis

Erinn M Hade, Rachel M Smith, Daniel A Culver, Elliott D Crouser, Erinn M Hade, Rachel M Smith, Daniel A Culver, Elliott D Crouser

Abstract

Introduction: Sarcoidosis is a systemic granulomatous disease of unknown cause afflicting young to middle-aged adults. The majority of patients with active pulmonary sarcoidosis complain of overwhelming fatigue, which often persists despite administration of immune-modulating drugs typically used to treat sarcoidosis. Nicotine offers an alternative to conventional treatments, which are associated with a spectrum of serious untoward effects, including diabetes mellitus, osteoporosis, bone marrow suppression, severe infections, cirrhosis. The described pilot randomized trial aims to provide preliminary data required to design subsequent Phase II/III trials to formally evaluate nicotine as a novel low-cost and highly-effective, safe treatment option for patients with active pulmonary sarcoidosis.

Methods: and Design: This is a randomized double-blind controlled trial of adults with confirmed pulmonary sarcoidosis, allocated in equal proportion to sustained release transdermal nicotine or placebo patch. The primary objective outcome is the improvement in forced vital capacity at study week 26 from baseline measurement. Secondary measures include lung texture score, and self-reported outcomes including the Fatigue Assessment Scale, the St George's Respiratory Questionnaire, and the Sarcoidosis Assessment Tool.

Discussion: Current therapies for active pulmonary sarcoidosis, remain either expensive and often with numerous side-effects, as with novel industry developed therapies, or with reduced quality of life, as with corticosteroids. Nicotine therapy provides promise as a safe, available, and cost-effective intervention strategy, which we expect to be acceptable to patients.

Clinicaltrialsgov: NCT02265874.

Keywords: Forced vital capacity; Nicotine; Pulmonary sarcoidosis; Quality of Life; Randomized controlled trial.

Conflict of interest statement

The authors report no competing interests.

© 2020 The Authors. Published by Elsevier Inc.

Figures

Fig. 1
Fig. 1
Inclusion & Exclusion criteria.
Fig. 2
Fig. 2
Study Timeline and Follow up.
Fig. 3
Fig. 3
Study recruitment.

References

    1. Hinz A. Fatigue in patients with sarcoidosis, compared with the general population. Gen. Hosp. Psychiatr. 2011;33(5):462–468.
    1. de Kleijn W.P. Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc. Diffuse Lung Dis. 2009;26(2):92–97.
    1. Denys B.G. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clin. Sci. (Lond.) 2007;112(5):281–289.
    1. Newman L.S. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am. J. Respir. Crit. Care Med. 2004;170(12):1324–1330.
    1. Carlens C. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am. J. Respir. Crit. Care Med. 2010;181(11):1217–1222.
    1. Valeyre D. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax. 1988;43(7):516–524.
    1. de Jonge W.J., Ulloa L. The alpha 7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br. J. Pharmacol. 2007;151(7):915–929.
    1. Kox M. GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochem. Pharmacol. 2009;78(7):863–872.
    1. Yanagita M. Nicotine modulates the immunological function of dendritic cells through peroxisome proliferator-activated receptor-gamma upregulation. Cell. Immunol. 2012;274(1–2):26–33.
    1. Zhang S., Petro T.M. The effect of nicotine on murine CD4 T cell responses. Int. J. Immunopharm. 1996;18(8–9):467–478.
    1. Ingram J.R. Vol. 2008. Gastroenterol Res Pract; 2008. Nicotine enemas for active Crohn's colitis: an open pilot study; p. 237185.
    1. Blanchet M.R., Israel-Assayag E., Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. Am. J. Respir. Crit. Care Med. 2004;169(8):903–909.
    1. Julian M.W. Nicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest. 2013;143(2):461–470.
    1. Chen E.S., Moller D.R. Sarcoidosis-scientific progress and clinical challenges. Nat. Rev. Rheumatol. 2011;7(8):457–467.
    1. Morgenthau A.S., Iannuzzi M.C. Recent advances in sarcoidosis. Chest. 2011;139(1):174–182.
    1. Cox C.E. Health-related quality of life of persons with sarcoidosis. Chest. 2004;125(3):997–1004.
    1. Vermeire S., Van Assche G., Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract. Res. Clin. Gastroenterol. 2009;23(1):101–112.
    1. Poltavski D.V., Petros T. Effects of transdermal nicotine on prose memory and attention in smokers and nonsmokers. Physiol. Behav. 2005;83(5):833–843.
    1. Baughman R.P. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. 2006;174(7):795–802.
    1. Behr J. A small change in FVC but a big change for IPF: defining the minimal clinically important difference. Am. J. Respir. Crit. Care Med. 2011;184(12):1329–1330.
    1. Baughman R.P. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 2009;136(2):526–535.
    1. Bergin C.J. Sarcoidosis: correlation of pulmonary parenchymal pattern at CT with results of pulmonary function tests. Radiology. 1989;171(3):619–624.
    1. Muller N.L. Sarcoidosis: correlation of extent of disease at CT with clinical, functional, and radiographic findings. Radiology. 1989;171(3):613–618.
    1. Erdal B.S. Quantitative computerized two-point correlation analysis of lung CT scans correlates with pulmonary function in pulmonary sarcoidosis. Chest. 2012;142(6):1589–1597.
    1. Lower E.E., Harman S., Baughman R.P. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008;133(5):1189–1195.
    1. Picciotto M.R., Brunzell D.H., Caldarone B.J. Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport. 2002;13(9):1097–1106.
    1. Salin-Pascual R.J. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J. Clin. Psychiatr. 1996;57(9):387–389.
    1. Crouser E.D. Diagnosis and detection of sarcoidosis. An official American thoracic society clinical practice guideline. Am. J. Respir. Crit. Care Med. 2020;201(8):e26–e51.
    1. Harris P.A. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 2009;42(2):377–381.
    1. Crapo R.O., Morris A.H., Gardner R.M. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am. Rev. Respir. Dis. 1981;123(6):659–664.
    1. Barr J.T. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin. Therapeut. 2000;22(9):1121–1145.
    1. Jones P.W., Quirk F.H., Baveystock C.M. The St george's respiratory Questionnaire. Respir. Med. 1991;85(Suppl B):25–31. discussion 33-7., P.
    1. Judson M.A. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. Am. J. Respir. Crit. Care Med. 2015;191(7):786–795.
    1. Michielsen H.J., De Vries J., Van Heck G.L. Psychometric qualities of a brief self-rated fatigue measure: the Fatigue Assessment Scale. J. Psychosom. Res. 2003;54(4):345–352.
    1. Liu G.F. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat. Med. 2009;28(20):2509–2530.
    1. The Prevention and Treatment of Missing Data in Clinical Trials. 2010. Washington (DC)
    1. Nouri-Shirazi M., Guinet E. A possible mechanism linking cigarette smoke to higher incidence of respiratory infection and asthma. Immunol. Lett. 2006;103(2):167–176.
    1. Matsunaga K. Involvement of nicotinic acetylcholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J. Immunol. 2001;167(11):6518–6524.
    1. Johnstone E. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin. Pharmacol. Ther. 2006;80(4):319–330.
    1. Hukkanen J., Jacob P., 3rd, Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 2005;57(1):79–115.
    1. Nizri E. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J. Immunol. 2009;183(10):6681–6688.
    1. Pickworth W.B., Bunker E.B., Henningfield J.E. Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology (Berlin) 1994;115(1–2):9–14.
    1. Henningfield J.E. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol. Ther. 2009;123(1):1–16.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera